Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma

• Status: Completed
• Trial end date: 2012-01-06
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Aurora kinase inhibitor AT9283 (AT9283) may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase I trial is studying the side effects and best dose of AT9283 in treating patients with advanced or metastatic solid tumors or non-Hodgkin's lymphoma.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: NCIC Clinical Trials Group
• Collaborator: Astex Pharmaceuticals, Inc.

Criteria

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed diagnosis of 1 of the following:

• Advanced and/or metastatic solid tumor

• Advanced or metastatic non-Hodgkin's lymphoma refractory to standard therapy

• Clinically or radiologically documented disease

• No tumor marker elevation as only evidence of disease

• No untreated brain or meningeal metastases

• Treated and stable brain metastases allowed provided they are asymptomatic and do not require steroids

PATIENT CHARACTERISTICS:

• ECOG performance status 0-2

• Absolute granulocyte count ≥ 1,500/mm³

• Platelet count ≥ 100,000/mm³

• Creatinine ≤ 1.25 times upper limit of normal (ULN) OR creatinine clearance ≥ 50 mL/min

• Bilirubin normal

• ALT and AST ≤ 2 times ULN (≤5 times ULN if liver metastases are present)

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use two effective methods of contraception

• No untreated or uncontrolled hypertension, cardiovascular conditions, or symptomatic cardiac dysfunction

• No active or uncontrolled infections

• No serious illness or medical condition that would preclude study treatment

PRIOR CONCURRENT THERAPY:

• At least 2 weeks since prior major surgery and recovered

• At least 3 weeks since prior palliative radiotherapy and recovered

• Low-dose, nonmyelosuppressive radiotherapy may be allowed

• At least 3 weeks since prior chemotherapy for solid tumors and recovered

• No more than 2 prior cytotoxic chemotherapy regimens for metastatic disease

• At least 4 weeks since prior steroids

• No limitations on prior therapy for patients with non-Hodgkin's lymphoma

• Prior hormonal, immunologic, biologic or signal transduction inhibitor therapy allowed

• No other concurrent investigational agents

• No other concurrent anticancer therapy